By Fineline Cube 
Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) and Nanjing ProBio, a subsidiary of GenScript Biotech Corporation, entered into a strategic cooperation agreement to jointly develop next‑generation antibody‑drug conjugates (ADCs). The partnership will focus on the discovery and R&D of several innovative targeted ADCs, leveraging MicuRx’s expertise in small‑molecule safety and ProBio’s platform capabilities.
MicuRx’s Foundation in Small‑Molecule Innovation
- Core Strength: MicuRx has a long‑standing track record in designing small‑molecule drugs with superior safety profiles.
- Portfolio Highlight: Its first approved product, Contezolid tablets, has markedly reduced common toxicities such as myelosuppression and peripheral neuropathy seen in similar agents.
- Platform Edge: The company’s newly developed STOPIN (Soft Topoisomerase Inhibitor) platform is engineered to mitigate dose‑limiting toxicities that often plague next‑generation ADCs.
ProBio’s Complementary Capabilities
- ADC Expertise: Nanjing ProBio brings to the table advanced conjugation chemistry, linker‑stability technology, and robust preclinical pipelines.
- Synergy: By combining MicuRx’s small‑molecule optimization with ProBio’s ADC conjugation expertise, the alliance aims to produce safer, more efficacious targeted therapies for oncology and other high‑need indications.
Strategic Outlook
The collaboration positions both companies at the forefront of precision oncology, tapping into the rapidly expanding ADC market projected to exceed $50 billion by 2030. The joint R&D efforts are expected to shorten development timelines, reduce attrition rates, and deliver novel therapeutic options to patients with unmet medical needs.-Fineline Info & Tech